OBJECTIVE: The objective of this study was to evaluate the in vitro antifungal activity of propolis extract against yeasts Candida albicans and Candida non-albicans isolated from vaginal exudates, in comparison with nystatin. DESIGN: Ninety-seven (97) vaginal yeasts strains were evaluated. These strains were obtained from different clinical conditions, isolated and stored at the Sector of Medical Mycology of the State University of Maringá (Paraná, Brazil). The assays of susceptibility to nystatin and propolis extracts (PE) were conducted through microdilution in broth (National Committee for Clinical Laboratory Standards-NCCLS, M-27A Document of 1997). RESULTS: All the yeasts tested were inhibited by low concentrations of PE (maximum of 393.19 mug/mL of the total flavonoid content), including an isolate resistant to nystatin, regardless of the clinical conditions of the women and the species of yeast isolated. CONCLUSIONS: The PE showed an outstanding performance against the tested vaginal yeast strains, and could be included among the novel therapeutic options for the treatment of vulvovaginal candidiasis.
OBJECTIVE: The objective of this study was to evaluate the in vitro antifungal activity of propolis extract against yeastsCandida albicans and Candida non-albicans isolated from vaginal exudates, in comparison with nystatin. DESIGN: Ninety-seven (97) vaginal yeasts strains were evaluated. These strains were obtained from different clinical conditions, isolated and stored at the Sector of Medical Mycology of the State University of Maringá (Paraná, Brazil). The assays of susceptibility to nystatin and propolis extracts (PE) were conducted through microdilution in broth (National Committee for Clinical Laboratory Standards-NCCLS, M-27A Document of 1997). RESULTS: All the yeasts tested were inhibited by low concentrations of PE (maximum of 393.19 mug/mL of the total flavonoid content), including an isolate resistant to nystatin, regardless of the clinical conditions of the women and the species of yeast isolated. CONCLUSIONS: The PE showed an outstanding performance against the tested vaginal yeast strains, and could be included among the novel therapeutic options for the treatment of vulvovaginal candidiasis.
Authors: Patrícia Alves de Castro; Marcela Savoldi; Diego Bonatto; Mário Henrique Barros; Maria Helena S Goldman; Andresa A Berretta; Gustavo Henrique Goldman Journal: Eukaryot Cell Date: 2010-12-30
Authors: Edílson Damke; Joyce K Tsuzuki; Diógenes A G Cortez; Izabel C P Ferreira; Thâmara A Bertoni; Márcia R Batista; Lucélia Donati; Terezinha I E Svidzinski; Márcia E L Consolaro Journal: BMC Complement Altern Med Date: 2011-05-04 Impact factor: 3.659
Authors: Flavia F Veiga; Marina C Gadelha; Marielen R T da Silva; Maiara I Costa; Brenda Kischkel; Lidiane V de Castro-Hoshino; Francielle Sato; Mauro L Baesso; Morgana F Voidaleski; Vanessa Vasconcellos-Pontello; Vânia A Vicente; Marcos L Bruschi; Melyssa Negri; Terezinha I E Svidzinski Journal: Front Microbiol Date: 2018-04-25 Impact factor: 5.640
Authors: Melyssa Negri; Tânia P Salci; Cristiane S Shinobu-Mesquita; Isis R G Capoci; Terezinha I E Svidzinski; Erika Seki Kioshima Journal: Molecules Date: 2014-03-07 Impact factor: 4.411
Authors: Patrícia Alves de Castro; Marcela Savoldi; Diego Bonatto; Iran Malavazi; Maria Helena S Goldman; Andresa A Berretta; Gustavo Henrique Goldman Journal: BMC Complement Altern Med Date: 2012-10-24 Impact factor: 3.659